Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Create Stock SIPAutomate your investments in this
Performance
Open
626.00Prev. Close
629.10Volume
20,34,527Total traded value
125 CrUpper Circuit
738.60Lower Circuit
492.40Fundamentals
| Market Cap | ₹23,551Cr |
| ROE | 8.61% |
| P/E Ratio(TTM) | 75.16 |
| EPS(TTM) | 8.19 |
| P/B Ratio | 6.22 |
| Dividend Yield | 0.00% |
| Industry P/E | 33.72 |
| Book Value | 99.01 |
| Debt to Equity | 0.12 |
| Face Value | 1 |
Understand Fundamentals
Financials
About Cohance Lifesciences
Suven Pharma is a contract development and manufacturing (CDMO) company providing services to global pharmaceutical and fine chemical innovators from research to commercial production. Its core principle is to consistently deliver on commitments, which has enabled its transformation from a domestic player to a global partner for major brands. The company has an excellent track record, having delivered more than 900 CDMO projects on time to its global clients.;
| Parent Organisation | Cohance Lifesciences |
| Managing Director | Dr. Vetukuri Venkata Prasada Raju |
| NSE Symbol | COHANCE |
Shareholding Pattern
Dec '24
Mar '25
May '25
Jun '25
Sep '25
Top Mutual Funds Invested(4)
Similar Stocks
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 39.77 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 31.74 | ||
| Wockhardt | NA (0.00%) | -428.76 | ||
| Concord Biotech | NA (0.00%) | 44.04 |